nanoTherics was established in 2007 with technologies and products resulting from more than 30 years combined leading edge research into use of magnetic nanoparticles for biomedical applications conducted at Keele University and University of Florida. The Company now provides a range of magnetic nanoparticle-based products.

These innovative technologies and products have been designed to offer faster, more efficient, scalable tools to improve research into genetic disease disorders with potential of taking these from research laboratories to the clinic.

A key range of products that the Company provides use nanoparticles and oscillating magnetic fields to accurately and rapidly transfect biomaterials including deoxyribonucleic acids (DNA) and ribonucleic acids (RNA) into cells. It applies a novel technique, which is proprietary to nanoTherics (patents pending), with the key major advantages over currently available transfection systems being:

	Rapid, scalable transfection.
	Significant performance improvements over other non-viral techniques.
	High transfection efficiency with lower vector and DNA doses.
	Excellent cell viability.
	Safer and less toxic.
	Ability to easily scale-up for high-throughput applications.
	Potential use in clinical applications.
	Significantly lower reagent costs compared to electroporation.

nanoTherics’s gene transfection studies have shown a significant performance enhancement over the best non-viral techniques currently on the market, demonstrating high levels of transfection whilst maintaining the viability of transfected cells - all at shorter transfection times and a lower cost. These key attributes afford a significant advantage over currently available transfection methods.